Literature DB >> 4402038

Evidence for a new type of dopamine receptor stimulating agent.

H Corrodi, K Fuxe, U Ungerstedt.   

Abstract

Mesh:

Substances:

Year:  1971        PMID: 4402038     DOI: 10.1111/j.2042-7158.1971.tb09916.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


× No keyword cloud information.
  30 in total

1.  Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control.

Authors:  R H Mindham
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

2.  Hypothermic action of bromocriptine.

Authors:  D B Calne; L E Claveria; J L Reid
Journal:  Br J Pharmacol       Date:  1975-05       Impact factor: 8.739

3.  Activity and acceptability of piribedil in Parkinson's disease: a multicentre study.

Authors:  P Rondot; M Ziegler
Journal:  J Neurol       Date:  1992       Impact factor: 4.849

4.  A new central direct dopaminergic stimulant: 1-(Coumaran-5-yl methyl)-4-(2-thiazolyl) piperazine hydrochloride (S 3608).

Authors:  J C Poignant; H Gressier; M Petitjean; G Regnier; R Canevari
Journal:  Experientia       Date:  1975-10-15

5.  Femoral vasodilatation produced by piribedil (ET495) and its metabolite S584 in the hindleg of the dog.

Authors:  W A Buylaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-08       Impact factor: 3.000

6.  Hyperthyroidism: specifically increased response to central NA-(alpha-)receptor stimulation and generally increased monoamine turnover in brain.

Authors:  U Strömbom; T H Svensson; D M Jackson; G Engström
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

7.  Further aspects of nomifensine pharmacology.

Authors:  B Costall; R J Naylor
Journal:  Br J Clin Pharmacol       Date:  1977       Impact factor: 4.335

Review 8.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

9.  Dopamine agonist and antagonist activities of piribedil (ET495)and its metabolites.

Authors:  B Costall; R J Naylor
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

Review 10.  Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.